NewcelX Ltd.

NewcelX Ltd. is a Switzerland-based biopharmaceutical company focused on developing cell-based and small-molecule therapies for neurodegenerative and metabolic diseases. Its current portfolio centers on stem-cell-derived and off-the-shelf regenerative medicine programs, including therapies for Type 1 diabetes, insulin-dependent Type 2 diabetes, amyotrophic lateral sclerosis, and other neurological conditions. The company’s work combines cell replacement, neuroscience, and translational research to address areas with significant unmet medical need. NewcelX Ltd. also develops a dual orexin-receptor agonist platform for sleep disorders and related neurological indications, reflecting a broader approach across metabolic, inflammatory, and central nervous system disorders. Headquartered in Kloten, Switzerland, NewcelX Ltd. operates as a clinical-stage biotechnology firm with research and development activities supporting its therapeutic pipeline.

Sector

Healthcare

Industry

Biotechnology

CEO

Mr. Ronen Twito CPA

Employees

9

Headquarters

Kloten, Switzerland

Website

newcelx.com